Latanoprost--a promising new glaucoma drug (Q39706170)

14 September 2017

0 references

Latanoprost--a promising new glaucoma drug (English)

1 reference

14 September 2017

Nagasubramanian S

1

1 reference

PMCID

505007

14 September 2017

language of work or name

English

0 references

publication date

1 January 1995

1 reference

British Journal of Ophthalmology

14 September 2017

1 reference

14 September 2017

79

1 reference

14 September 2017

1

1 reference

14 September 2017

3-4

1 reference

Prostaglandin F2 alpha-isopropylester eye drops: effects in normal human eyes

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=505007

Prostaglandin F2 alpha-isopropylester eye drops: effect on intraocular pressure in open-angle glaucoma

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=505007

The ocular hypotensive effects and side effects of prostaglandins on the eyes of experimental animals.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=505007

PhXA34--a prostaglandin F2 alpha analogue. Effect on intraocular pressure in patients with ocular hypertension

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=505007

Ocular effects of two different prostaglandin F2 alpha esters. A doublemasked cross-over study on normotensive eyes

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=505007

The effect of adding prostaglandin F2 alpha-isopropylester to timolol in patients with open angle glaucoma

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=505007

Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=505007

Maintained reduction of intraocular pressure by prostaglandin F2 alpha-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=505007

The effects of prostaglandin F2 alpha in the human eye

17 June 2018

1 reference

12 December 2020

The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes

1 reference

12 December 2020

The effect of prostaglandin F2 alpha on intraocular pressure in normotensive human subjects

1 reference

12 December 2020

Additivity of prostaglandin F2 alpha-1-isopropyl ester to timolol in glaucoma patients

1 reference

12 December 2020

PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers

1 reference

12 December 2020

Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2 alpha analogue (PhXA41). An in-hospital, placebo-controlled study

1 reference

12 December 2020

Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes

1 reference

12 December 2020

Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens

1 reference

12 December 2020

Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study

1 reference

12 December 2020

Identifiers

DOI

10.1136/BJO.79.1.3-A

1 reference

14 September 2017

1 reference

14 September 2017

1 reference

PMCID

505007